The article reports on the recommendation of the European Agency for the Evaluation of Medicinal Products that the intravenous (IV) Keppra drug of UCB be used in juvenile myoclonic epilepsy. The European Commission approved the IV formulation of Keppra for use as adjunctive therapy in the ...
The company's strategy for Keppra is to focus exclusively on penetrating the epilepsy market. The European Agency for the Evaluation of Medicinal Products has also recommended the drug for use in juvenile myoclonic epilepsy.EBSCO_bspPharmawatch Monthly Review...